Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy

Table 1 The individual patients' radiation dose-volume relationships, vorinostat dose, and any grade 3 adverse event

Age (years)	Gender	GTV (ccm)	ITV (ccm)	SBV (ccm)	V6 (%)	V12 (%)	V18 (%)	V24 (%)	V30 (%)	Vorinostat dose (mg)	DLT grade 3 adverse event	Other grade 3 adverse event
87	female	285	648	823.8	79	74	70	67	40	300	anorexia, fatigue
81	female	72.2	380	990.9	63	41	22	18	0	300
66	female	171	483	2292	45	37	19	15	3	200		rash (following cetuximab)
49	female	89.5	323	1291	43	38	33	25	11	200
47	female	198	414	2440	42	37	34	30	14	300
83	female	197	549	1114	41	29	24	19	3	400	diarrhea, anorexia, hyponatremia
55	male	87.7	867	1811	34	23	18	16	6	400
75	female	36.7	277	1516	31	14	11	8	0	400	diarrhea, fatigue, hypokalemia
62	male	114	324	2180	19	5	3	2	0	400
77	male	153	650	1972	18	7	3	3	1	300		fatigue (during pneumonia)
45	female	58.1	175	2163	16	7	5	4	0	400
82	male	75.5	330	2946	15	4	1	1	0	300		fatigue (during pneumonia)
77	female	164	625	1901	5	2	1	0	0	100
85	female	60.1	180	1256	4	2	2	1	0	400

Abbreviations: GTV = gross tumor volume; ccm = cubic centimeter; ITV = internal target volume; SBV = small bowel volume; V6-V30 = the relative volumes of small bowel receiving radiation doses of 6-30 Gy; DLT = dose-limiting toxicity.

ISSN: 1748-717X